Table 1 Effector and processing based on HDAC6 deacetylation activity of Hsp90

GR

Glucocorticoid receptor maturation in A431, A549 cells or serotonin pathways in mice

Mutations, trichostatin A (TSA) (1 μM), Tubacin (10 μM), ACY-738(2.5 μM) knock out or transgenesis

Espallergues et al. (2012); Hu et al. (2019); Jochems et al. (2015); Kovacs et al. (2005a, b); Lee et al. (2012); Murphy et al. (2005); Zhu et al. (2020)

ERα

Hippo pathway in ERα + or tamoxifen-resistant breast cancer

Tubacin (1 μM), Panobinostat (LBH589) (100 nM) or Dacinostat (LAQ824) (250 nM)

Fiskus et al. (2007); Yu et al. (2017)

HIF-1α

Glioblastoma growth and angiogenesis

LBH589 (40 nM) or TSA (500 nM)

Schoepflin et al. (2016); Yao et al. (2017); Zhang et al. (2010)

EGFR

Esophageal squamous cell carcinoma proliferation and migration

siRNA or Tubastatin (1 μM)

Tao et al. (2018); Kim et al. (2009); Gravina et al. (2013)

Kit

Growth inhibition, cell cycle arrest, apoptosis against malignant mast cell lines

AR-42 (3 μM)

Lin et al. (2010)

Her-2

Her-2 stability via the proteasome pathway in SK-BR-3 cells

Carbamazepine (CBZ) (100 μM) or TSA) (100 nM)

Kim et al. (2009); Gravina et al. (2013); Meng et al. (2011)

VEGFRs

Proteasomal degradation of vascular endothelial growth factor receptors

Suberoylanilide hydroxamic acid (SAHA) (1 μM), LAQ824 (300 nM) or TSA (30 nM) or Tubacin (100 nM)

Park et al. (2008); Verheyen et al. (2012)

AR

Proteasome degradation of AR in LNCaP cells or prostate cancer

siRNA, overexpression, genistein (25 μM), 4-HBAs (4-hydroxybenzoic acids) (50 μM), SAHA (10 μM), Sulforaphane (20 μM), Belinostat (PXD101) (0.5 μM) or 2‐75 (2.5 µM)

Hu et al. (2019); Gravina et al. (2013); Ai et al. (2009); Basak et al. (2008); Gibbs et al. (2009); Rosati et al. (2016); Seidel et al. (2016)

AhR

Aryl hydrocarbon receptor signaling in human aerodigestive epithelial cells

TSA (500 nM), SAHA (20 μM) or Tubacin (20 μM)

Kekatpure et al. (2009)

Rac1

Membrane ruffle formation and cell migration in MEFs

knock-out HDAC6

Gao et al. (2007)

Survivin

Autophagy and viability reduction in breast cancer cells

SAHA (1.4 μM)

Lee et al. (2016)

Bcr-Abl

Degradation of Bcr-Abl in human leukemia cells or FDCP-1 cells

LAQ824(100 nM), SAHA (5 μM), MRLB-223(10 μM) or siRNA

Rao et al. (2008); Bali et al. (2005); Lee et al. (2007); Newbold et al. (2013)

c-Raf

Degradation of c-Raf human in leukemia cells

Tubacin (3 µM) and siRNA

Rao et al. (2008)

tau

Degradation of tau in HEK293T or HeLa cells and tau pathology neurodegeneration in rTg4510 mouse models

Overexpression HDAC6, siRNA or tubastatin (25 mg/kg/day)

Selenica et al. (2014); Cook et al. (2012)

aurora-A

Migration and metastatic activity in breast cancer

MPT0G211 (10 μM) or tubastatin A (10 μM)

Hsieh et al. (2019)

IKKα

Proliferation and apoptosis in human myeloma cell line and primary myeloma cells

As₂O₃(5 μM)

Qu et al. (2012)

MIF

MIF stability via the proteasome pathway in cancer cells

siRNA or SAHA (5 μM)

Schulz et al. (2012)

cyclin D1 and CDK4

G1 growth arrest in lung cancer cells

NBM-T-BBX-OS01 (10 μM) or overexpression

Pai et al. (2015)

mutant p53

Preferential cytotoxicity for mutp53 tumor

SAHA (5 μM), siRNA, or A452(2 μM)

Li et al. (2011); Ryu et al. (2017b)

MMP-9

Migration and invasion activities in lung cancer

Honokiol (10 μM)

Pai et al. (2020)

NS5(Japanese Encephalitis Virus)

Viral RNA Synthesis

Tubacin (10 μM) or TBSA (10 μM)

Lu et al. (2017)